ABIONYX successfully increased capital and canceled the preemptive subscription rights of a class of people by issuing shares with warrants to Anmou

• C. Difficulty of shares with warrants for €3.4 million
• Subscription worth: €1.37 per share (together with warrants)
• 1 warrant is entitled to subject 1 share at a worth of three euros
• Train interval: 3 years
• Visibility prolonged till finish of 2025

TOLOUSE, France and LAKELAND, Mich.–(Enterprise Wire)–Supervisory Information:

ABIONYX Pharma, (FR0012616852 – ABNX – PEA PME eligible)A brand new era biotechnology firm devoted to discovering and creating modern therapies primarily based on the world’s solely pure recombinant apoA-I, introduced a profitable capital improve and the cancellation of pre-emptive subscription rights, bringing a certain quantity of advantages to a category of individuals by the issuance of as much as 2,472,000 new shares (every (with warrants hooked up), the subscription worth is 1.37 euros per share (with warrants hooked up), and practically 3.4 million euros have been raised.

Every new share shall be accompanied by a warrant, every warrant giving its holder the fitting to subscribe for 1 new share at a worth of €3.

Fundraising goal

The aim of this financing is to strengthen the corporate’s money place as a part of sepsis and U.S. improvement following a profitable pre-IND assembly with the FDA. The corporate’s monetary visibility has now been prolonged till the tip of 2025, with no additional drawdowns on the equity-linked financing facility.

Phrases and situations of subject

Pursuant to selections taken by the Board of Administrators on June 19 and 21, the CEO has right this moment totally subscribed for the next 2,472,000 abnormal shares with a par worth of €0.05 per share, every of which is accompanied by a subscription warrant for a brand new abnormal share. The issuance worth of the shares with warrants is 1.37 euros, which is equal to a rise in nominal capital of 123,600 euros and an issuance premium of three,263,040 euros.

The subscription worth for every share of the warrants hooked up is equal to the weighted common worth of the ten buying and selling days previous June 19, 2024, much less a ten% low cost, plus the estimated worth of the warrants of €0.18.

When shares with warrants are created, the warrants are indifferent from the shares.

This issuance accounts for roughly 7.62% of the share capital on the day of the issuance resolution.

The brand new shares have dividend rights similar to and have the identical rights as present shares. They’re topic to all provisions of the corporate’s articles of affiliation and are permitted to commerce on Euronext in the identical method as present shares.

Every warrant will entitle its holder to subscribe for one new share at a worth of €3.

These warrants are exercisable from November 30, 2024 to June 19, 2027.

The train of all warrants might outcome within the issuance of as much as 2,472,000 new abnormal shares, equal to gross further proceeds of €7,416,000.

This capital improve and the cancellation of the preemptive subscription rights of particular ethnic teams have been determined by the corporate’s board of administrators from June 19 to 21, 2024, approved by the corporate’s decision No. 20.

Supply and settlement

Settlement and supply are scheduled for Wednesday, July 3, 2024.

Difficulty proceeds

The gross proceeds from the difficulty of shares topic to warrants have been €3,386,640, web of €3,356,640 after deducting prices associated to the difficulty.

The train of all warrants will generate a further gross proceeds of €7,416,000.

Shareholder construction

The variety of shares that could be issued represents roughly 7.62% of the variety of shares issued earlier than the issuance, and seven.08% of the variety of shares with warrants hooked up after the issuance.

For instance, a shareholder who holds 1% of the share capital of ABIONYX earlier than the deliberate issuance will maintain 0.93% of the share capital of ABIONYX after the issuance of warrants (if the capital improve is totally subscribed) and 0.87% of the share capital (if all warrants are exercised) ).

Shareholding ratio of shareholders earlier than and after capital improve

Based mostly on data dropped at the eye of the corporate, particularly bearer shareholders by declarations that cross thresholds (authorized and statutory).

A few of the particular person shareholders listed within the desk above maintain all or a part of their pursuits by holding firms that they handle and management.

Lack of prospectus

In response to Normal Regulation 211-3 of the Monetary Market Authority (AMF), this issuance is not going to produce a prospectus that’s topic to AMF approval.

threat components

The chance components are described within the 2023 Normal Registration Doc No. D.24-0385 (Chapter 3) filed with AMF on April 30, 2024, accessible on the Firm’s web site: www.abionyx.com and the AMF web site: www .amf-france.org.

Variety of shares constituting share capital

Following the issuance of shares with warrants, the share capital now quantities to €1,746,550.60. It’s divided into 34,931,012 abnormal shares with a par worth of €0.05, equal to 34,931,012 theoretical voting rights.

About ABIONYX Prescription drugs

ABIONYX Pharma is a next-generation biotechnology firm centered on creating modern medicines to deal with even the rarest illnesses for which there are not any efficient or present remedies. The corporate leverages its broad experience in lipid science and its differentiated apoA-I-based know-how platform to speed up the event of novel therapies. ABIONYX Pharma is working to basically enhance the therapy of sepsis and significant care.

View supply model on businesswire.com: https://www.businesswire.com/information/dwelling/20240701444059/en/

new capital
investor relations
Nicholas Fossey
Louis-Victor de Louvier
abionyx@newcap.eu
+33 (0)1 44 71 98 53

new capital
media relations
Arthur Ruyer
abionyx@newcap.eu
+33 (0)1 44 71 00 15

Supply: ABIONYX Pharma